Informations bibliographiques
Ligne directriceWHO consolidated guidelines for the management of common childhood illness: management of asthma in children and adolescents and bronchiolitis in infants and young children
Année de publication2026
Institution émettriceWorld Health Organization
Recommandation
Mise à jour
Intravenous (IV) short-acting beta2 agonist (SABA) should be used as a potential second-line therapy for severe paediatric asthma exacerbations in addition to standard first-line therapy with inhaled/nebulized medicines (SABA and ipratropium) and systemic corticosteroids in health care facilities.
Recommandé en faveur
Forte
Certitude des données probantes
Élevée